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PENILAIAN FARMAKOEPIDEMILOGI TERAPI DRUG ANTIKULAT 
YANG DIGUNAKAN DI HOSPITAL UNIVERSITI SAINS MALAYSIA 
(HUSM  )  
 
 
ABSTRAK 
 
 
Pada hari ini, mengurus jangkitan kulat merupakan satu cabaran yang 
terpaksa dihadapi oleh doktor di seluruh dunia. Jangkitan kulat dianggap sebagai 
penyebab utama morbiditi dan mortaliti dalam kalangan pesakit-pesakit, terutamanya 
pesakit-pesakit yang yang mempunyai immunokompromi yang  teruk. Dalam 
penyelidikan ini, kajian retrospektif telah dijalankan untuk menentukan epidemiologi 
dan pengurusan jangkitan kulat dalam kalangan pesakit luar dan pesakit dalam di 
Hospital Universiti Sains Malaysia (HUSM). Data telah dibahagikan kepada data 
pesakit luar dan pesakit dalam. Data pesakit dalam telah dipungut secara prospektif 
daripada rekod perubatan. Jumlah pesakit yang merupakan kes-kes jangkitan kulat 
yang disahkan berdasarkan laporan makmal terdiri daripada 290 orang. Melayu 
merupakan kaum yang majoritinya dikesan mengalami jangkitan kulat. Kumpulan 
umur 18-27 tahun mempunyai kekerapan yang tertinggi dangan jumlah 31%. Wanita 
(212,73%) mempunyai kekerapan yang lebih tinggi daripada lelaki (78, 26.9%). Wad 
obstetrik di HUSM telah menerima lebih banyak pesakit jangkitan kulat (130, 
44.8%). Separuh daripada pesakit itu (145, 50%) telah dimasukkan ke hospital 
selama 1 hingga 4 hari. Kematian berjumlah lebih kurang 9.3% (27 pesakit). 
Diabetes melitus (47,18.6%) merupakan  komorbiditi yang paling tinggi. 
Penggunaan antibiotik merupakan faktor risiko umum yang melibatkan 199 (68.6%) 
orang. Candida albicans dianggap sebagai kulat yang paling kerap dikenal pasti. Di 
antara pesakit-pesakit tersebut, 81 orang (27.9%) telah dirawat dengan terapi drug 
antikulat. Fluconazole ialah drug yang paling kerap digunakan bagi merawat pesakit-
 xix
pesakit jangkitan kulat yang dimasukkan ke hospital. Data pesakit luar telah 
dikumpul secara retrospektif daripada preskripsi perubatan yang diberikan. Terdapat 
1090 pesakit luar yang dirawat dengan terapi drug antikulat dalam tempoh kajian ini 
dijalankan mulai 1 Jan. 2005 hingga 30 Jun 2005. Wanita (677, 62.1%) merupakan 
majoriti pesakit dalam kalangan pesakit luar. Orang Melayu (979, 89%) merupakan 
kumpulan etnik yang paling ramai menerima rawatan, diikuti oleh Cina (94, 8.6%), 
India (14, 1.3%). Klinik keluarga telah menerima bilangan pesakit yang paling 
banyak. Kulit (927, 85%) merupakan sistem yang paling banyak dijangkiti 
berbanding sistem tubuh badan yang lain. Miconazole (818, 75%) merupakan 
rawatan yang paling kerap diberikan kepada pesakit. Lebih kurang 97.7 % preskriber 
terdiri daripada pegawai perubatan. Sebagai kesimpulan, kajian ini telah 
mengenalpasti pola umum jangkitan kulat dan pengubatan antikulat yang digunakan 
bagi merawat pesakit-pesakit yang dimasukkan ke wad perubatan dan rawatan yang 
diberikan kepada mereka yang datang ke klinik rawatan pesakit luar di HUSM. Ciri-
ciri umum jangkitan kulat dalam persekitaran kita didapati konsisten dengan 
spektrum kajian yang lebih luas yang dijalankan di merata dunia. Dapatan kajian ini 
akan membantu pembuat dasar dan pegawai perubatan agar dapat mengawal dengan 
lebih baik serta mengurus jangkitan kulat di Malaysia degan lebih baik. 
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PHARMACOEPIDEMIOLOGICAL EVALUATION OF ANTIFUNGAL 
DRUG THERAPY USED IN HOSPITAL UNIVERSITI SAINS MALAYSIA 
(HUSM  )  
 
 
ABSTRACT 
 
 Today, managing fungal infection is one of the challenges doctors have to 
face worldwide. Fungal infection is considered as one of the main causes of 
morbidity and mortality among patients, especially those who are severely 
immunocompromised. In the current work, retrospective study was undertaken in 
order to determine the epidemiology and management of fungal infection among 
both outpatients and hospitalized patients at Universiti Sains Malaysia Hospital 
(HUSM). The data were divided into outpatients and hospitalized patients. Data of 
hospitalized patients were collected from the medical record.  The total numbers of 
patients with confirmed cases of fungal infection based on laboratory investigation 
were 290 patients. Majority of study subjects with fungal infections are Malay. The 
age group 18-27 years had high frequency accounting to 31%. Females (212, 73.1%) 
were diagnosed more for fungal infections than males (78, 26.9%) probably due to 
vaginal candidiasis. The obstetrics ward recorded more fungal infected patients (130, 
44.8%) than other wards. Half of the patients (145, 50%) were hospitalized between 
1-4 days.  Death, among the fungal infected patients of this study was 27 (9.3%).  
Diabetes mellitus (47, 18.6%), seems to be the most frequently co-morbidity disease. 
Antibiotic usage was the common risk factor associated with fungal infection 
accounting for 199 (68.6%) patients. Candida albicans is the most frequent identified 
fungi (169, 58%). Among the patients, 81 (27.9%) were treated with antifungal drug 
therapy. Fluconazole was the most common drug used to treat the hospitalized fungal 
 xxi
infected patients. Data of outpatients was collected retrospectively from the medical 
prescriptions.  There were 1090 outpatients treated with antifungal drug therapy 
during the study period from 1 Jan. 2005 to 30 of June 2005. Females (677, 62.1%) 
were the majority of patients among the outpatient. Malay was accounted as the most 
among the ethnic groups (979, 89.8%); followed Chinese (94, 8.6%), Indian (14, 
1.3%). Family clinic has received most patients.  Skin (927, 85%) was the most 
affected system compared to other body systems. Miconazole (818, 75%), was most 
frequently given to the patients. About 97.7% of the prescribers were medical 
officers according to the prescription record. The general features of fungal infection 
in this setting were similar to studies conducted worldwide. In conclusion, the 
current study has identified the general pattern of fungal infection and the use of 
antifungal medication given to patients admitted to the medical wards and to those 
who came to the outpatients’ clinics of the USM Hospital. 
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CHAPTER ONE 
INTRODUCTION 
 
1.1 BACKGROUND 
Fungi are widely distributed in nature. There are around 250,000 named 
species, but about 500 kinds have been recognized to cause disease (mycosis) in 
human (Richardson and Warnock, 2003). 
Fungal infections have recently become sources of growing risk to human 
health, particularly in persons with a compromised immune system (National 
Institute of Allergy and Infectious Diseases, 2007). Normally, fungi are connected 
with complex disease entities in complicated medical patients (e.g. Cryptococcosis in 
Acquired Immune Deficiency Syndrome (AIDS) patients or Aspergillosis in bone 
marrow or organ transplant patients).   
Pittet et al (1997) reported that the mortality rates due to fungal infections 
were significantly higher than those related to other organisms. 
The use of a high amount of antifungal drugs can lead to drug resistance by 
fungi microbes, especially in hospitals, which increase the spreading of hospital-
acquired infections. The recent studies have documented resistance of Candida's 
species to fluconazole and other azole and triazole drug, which are used widely in 
systemic fungal diseases (National Institute of Allergy and Infectious Diseases, 
2007). 
 
1.1.1 Infection 
1.1.1(a) Definition of infection 
According to the Infectious Diseases Society of America (IDSA, 1980), an 
infection was described as “the attacking of the body’s natural barriers by 
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microscopic organism such as bacterial, fungal, viral, or parasitic, which multiplies 
to make symptoms.” 
   
1.1.1 (b) Hospital-acquired infections     
A hospital-acquired infection is described as one that develops at least 48 
hours after the patient is admitted to the hospital, or up to 48 hours after being 
discharged. Outside this period, infections are considered to be community-acquired 
(Jamieson, 2008). 
 
1.1.2 Significance, classification and structure of fungi  
1.1.2 (a) Significance of fungi   
 Fungi are not always harming or transporting diseases, since they are 
sometimes beneficial (Talaro, 2008). Fungi are sometimes quite useful to human and 
play an essential role in human lives. Fungi are eukaryotes and heterotrophy that 
absorb their food by secreting digestive chemicals. Digesting biological substances 
found in the environment around fungi helps increasing the fertility of lands used in 
agriculture (fungi break down dead plants and animals and break down organic 
matter and returning essential mineral to the soil). Fungi are competing with bacteria 
for nutrients and space. Thus, several kinds of antibiotics are produced from fungi to 
fight bacterial infections (Talaro, 2008). In addition, some fungi yeast like 
Saccharomyces cerevisiae are known as baker's yeast because they are used in 
making bread, and they are also used to ferment beer and wine (Talaro, 2008). 
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1.1.2 (b) Classification of fungi 
There are three major types of fungi: yeasts, moulds and dimorphic fungi     
i. Yeasts     
 They are small oval or round in shape, predominantly unicellular, e.g. 
Candida spp.   
ii. Moulds 
 Grow as branching filments which are called hyphae, and connected to 
form a mass, known with mycelium, e.g. Mucor spp.  And Ttrichophyton spp.   
 
iii. Dimorphic fungi 
 This type is capable to changing and existing in both mould and yeast forms. 
The yeast always forms in the body while the filamentous one forms in the 
environment, e.g. Histoplasma spp.  And Sporothrix spp. (Richardson and Warnock, 
2003) 
 
1.1.2 (c) Structure of fungi    
 Fungi have defined nucleus with both DNA and RNA. They have a 
complex cell wall that contains sterols. Yeast is single cell organisms that reproduce 
by budding, whereas moulds grow by developing filamentous (Inglis, 2003).     
 
1.1.2 (d) Morphology of pathogenic fungi 
The pathogenic fungi that infect humans are non-motile eukaryotes, which 
are reproduced by sporulation. This organism exists in two forms viz: filamentous 
molds and unicellular yeast. In addition, these forms of morphology are not mutually 
exclusive and it depends on the growth conditions (Cleary et al., 2005).  
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1.1.3 Fungal infection  
1.1.3 (a) Infectious diseases due to fungi   
Fungal infection has become one of the most dangerous diseases that cause 
morbidity and mortality among the patients.  Many reasons and factors such as 
advances in medical technology and the development of new diagnostic and 
treatment which lead to infections of fungi among the pations and increased the life 
expectancy of critically ill patients. On the other hand, Candidiasis remains as the 
most common fungal infection in immunosupressed patients. Aspergillosis, 
zygomycosis and others invasive filamentous fungal infections are major problem for 
certain groups of patients (National Foundation for Infectous Diseases  1998)    
 
1.1.3 (b) Types of fungal infection 
The general name of the disease caused by fungi in human is called Mycoses.  
Fungus always lives in association with humans and might be present in the 
environment. Until few years ago, severe superficial infections as well as systemic 
infections caused by fungal micro organisms were very uncommon. However, fungal 
infections such as foot infections, oral and vaginal thrushes were the common 
diseases known to individuals.  
The incidence of serious systemic fungal infections has increased during the 
recent years. There are many factors which lead to fungal infections such as 
widespread use of broad-spectrum antibiotics (eliminate or decrease the non 
pathogenic bacterial population that normally competes with fungi). Other factors are 
the increase in the number of individuals with reduced immune responses due to 
Acquired Immunodeficiency Syndrome (AIDS), the action of immunosuppressant 
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drugs, or cancer chemotherapy agents. These reasons have lead to an increase in the 
prevalence of systemic fungal infections (Rang & Dale., 1999).        
 Fungi (mycoses) which cause infections disease to the human can be 
classified into a number of broad groups according to the initial site of infection. This 
classification shows the different groups of fungi and the way in which the site 
affected is related to the route by which the fungus enters to the body (Cleary et al., 
2005). 
 
i. Superficial mycoses 
These types of fungal infections involve only the outer layers of the skin and 
hair. These infections are often harmless that patients do not recognize their 
condition. The most famous example for these mycoses is Malasseziasis (Tinea 
versicolor). 
 
ii. Cutaneous mycoses 
            In the case of cutaneous mycoses the fungal extend deeper into the epidermis 
and also may infect the nails as well. The most common example for these mycoses 
is dermatophytosis. (Cleary et al., 2005). 
 
iii. Subcutaneous mycoses 
These kinds of fungal microorganisms are chronic. It leads to localized 
infections of the skin and subcutaneous tissue following the traumatic implantation 
of the etiologic agent. The example for these mycoses is sporotrich. (Cleary et al., 
2005). 
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iv. Systemic mycoses 
This type of mycoses is caused by dimorphic fungal pathogens in the internal 
organs. They often overcome the physiological and cellular defenses of the normal 
human host by changing their morphological form.  Most organs commonly affected 
are the lungs and gastrointestinal tract (Cleary et al., 2005). 
 
v. Opportunistic mycoses   
These types of mycoses cause fungal infections for the human body in the 
immunocompromised patients when the normal defense mechanisms are weak, an 
example of that is AIDS patients, more aggressive cancer and post-transplantation 
chemotherapy and the use of antibiotics, cytotoxins, immunosuppressive, 
corticosteroids and other macro disruptive procedures that result in lowered 
resistance of the host. 
  The organisms involved in these infections are cosmopolitan fungi, which 
have a very low inherent virulence.  The increased incidence of these infections and 
the diversity of fungi causing them; have paralleled the emergence of AIDS, more 
aggressive cancer and post-transplantation chemotherapy and the use of antibiotics, 
cytotoxins, immunosuppressive, corticosteroids and other macro disruptive 
procedures that result in lowered resistance of the host. The examples for these 
mycoses are Cryptococcus, Aspergillosis and Mucomycosis (Cleary et al., 2005). 
 
 vi. Non opportunistic fungi (primary pathogens) 
  Usually the primary pathogens cause diseases in the immunologically normal 
host. The most common examples for these mycoses are Histoplasmosis, 
Blastomycosis, and occidioidomycosis (Cleary  et al., 2005). 
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1.1.3 (c) Pathology of fungal infection 
The information of fungi are very little among the people, because many 
people think that the fungi, indicates only an organism that causes skin infections. 
However, actually fungi have major effect on the health and people life all around 
the world. Fungi cause a different types of clinical diseases, from simple superficial 
problems to very serious and harmful systemic infections (Schaechter et al., 2007). 
Calderone and Sihlar, (2002) mentioned that pathogenic fungi cause a variety 
of infections, which can be life-threatening. The infection can enter the human body 
through skin contact, inhalation, and translocation across physical barriers pursuant 
to host defects, accidental or iatrogenic abridgement of epithelial integrity.   
 
1.1.3 (d) Transmission of fungal infection 
Most fungi live in the soil or on plants. They are transmitted to humans by 
contact with fungus or its spores. They are frequently inhaled (e.g. Aspergillus spores 
and Cryptococcus), but they can also enter to the body through the broken skin. 
Some other cataneous mycoses are transmitted by contact with infected skin area, or 
by direct contact with a lesion on the skin of an infected human or animal (e.g. 
ringworm on cats (Lee and Bishop, 2002).        
  
1.1.3 (e) Signs and symptoms of fungal infection 
The signs and symptoms of fungal infection differ in accordance to the 
infected   parts of the body.  Often superficial fungal infections, such as jock itch, 
vaginal yeast, athlete's foot, and ringworm are typically annoying, but they are not 
very serious. Their symptoms generally include itchy, dry, red, scaly, or irritated 
skin. In addition, there are systemic fungal infections often begin in the lungs and 
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take time to develop. Furthermore, severe infections occur in people, whose immune 
systems have been weakened, allowing the infection to spread beyond the lungs to 
other organs. Moreover, symptoms of systemic fungal infections depend on which 
organs become infected and may include respiratory problems, extreme tiredness, 
coughing, weight loss, fever, night sweats, and headache (Human diseases and 
conditions, 2007) 
 
1.1.3 (f) Factors contributing to fungal infection 
There are a number of factors contributing to patient’s susceptibility to 
infection such as medical procedures, which lead to weakness of patient’s immune 
system.   These factors are summarized by Lee and Bishop, (2002) as transplant in 
organ surgery with administration of immunosuppressive drugs; prolonged broad 
spectrum antibiotic therapy, which destroys the normal flora; other invasive therapies 
such as intravenous total parenteral nutrition (TPN) - this involves the use of 
solutions of glucose, which inhibit bacterial growth but favor the growth of fungi 
such as Candida albicans. The use of fat emulsion in TPN also encourages the 
growth of Malassezia further, an otherwise harmless superficial fungus. Other 
factors include Continuous Ambulatory Peritoneal Dialysis (CAPD) - this is used to 
haemodialyse patients with renal failure (RF), the main problem is the risk of fungal 
infection as well as bacterial infection through the indwelling cannulae; and from 
contaminated equipment or material.      
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1.1.4 Pharmacoepidemiolog  
1.1.4 (a) Definitions   
 Pharmacoepidemiology was described as the study of the utilization and 
effects of drugs among large numbers of people 
The word Pharmacoepidemiology consists of two components, one is ‘phamaco’ and 
the other is ‘epidemiology’.  
1.1.4 (b) Epidemiology 
Epidemiology can be defined as the study of the distribution and determinants 
of diseases in populations 
 
1.1.4 (c) Important of Pharmacoepidemiology: 
Study of pharmacoepidemiology is extremely important because there are 
numbers of significant and contributions that can be made by pharmacoepidemiology 
such as   new information about the drug effects and drug costs.  Moreover by 
applying research studies of pharmacoepidemiology can obtain large information 
about new adverse drug reactions and drugs safety.  Reassurance about drug safety is 
one of the most important contributions that can be made by pharmacoepidemiology 
studies. Also use of pharmacoepidemiology is very useful and effect in the clinical 
trial method for the drugs before sending to the market. (Strom and Kimmel, 2006) 
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1.1.4 (d) Epidemiology of fungal infection 
 Fungal infections have become a major concern in our life as a result of 
many diseases such as nosocomial infections that is associated with significant 
mortality, longer hospital stays and higher health care costs (Klein and 
Watanakunakron, 1979; Edmond et al., 1999).  
The study of Toscano and Jarvis (1999) from the national foundation for 
infectious disease, reported that throughout the few decades, researches in advances 
in medical technology, development of new diagnostics and treatment approaches 
lead to increase in the life expectancy of seriously ill patients. They added that 
presence of the global Human Immunodeficiency Virus (HIV) epidemic has resulted 
in an increase in severely ill immunocompromised hospitalized patients, 
accompanied by more reports of fungal infections. 
The data from the National Nosocomial Infections Surveillance (NNIS) 
(1994) showed that Candida spp. now ranks as the fourth most common cause of 
nosocomial blood stream infections in United States, and the prevalence of systemic 
fungal infections has increased significantly during the past decade (Pfaller et al, 
1998).   
  Segal et al, (2007) and Ng (1994) declared that there are a lot of factors that 
associated with increase of fungal infections particularly invasive fungal infections 
(IFIs) among many patients, due to great use of bread-spectrum antibiotics and 
immunosuppressive agent.  
IFIs is associated with high mortality and morbidity among patients with 
acute  leukemia and receipt of an allogeneic hematopoietic stem cell transplant 
(HSCT),  central venous catheters, intensive care of low birth weight infections  and 
the acquired immunodeficiency syndrome (AIDS) epidemic. 
11 
 
Caston-Osorio et al., (2008) revealed that the use of wide amount of azole 
prophylaxis for Candida spp. might associate with high rate of incidence of many 
other fungal infections, such as Aspergillosis spp. 
 Shao et al., (2007) from Taiwan reported that the Candida albican, 
Cryptococcus neoformans and Aspergillus along with the use of high amount of   
antifungal prophylaxis, were the most causes agents of invasive fungal infections 
(IFIs). But today, the epidemiology of IFI has been shifted to others agents and 
factors of the fungal infections such as rise of non-albicant Candida, non-fumigatus 
Asperjillus and many others type of fungal microorganism from both main type of 
fungi (yeast, moulds). These new recognized fungal infections are associated with 
with morbidity and mortality (Shao et al., 2007) 
 
1.1.5 Cost of antifungal drugs  
Pharmacoeconomics refers to the scientific discipline that analysis cost of 
drugs therapy to health care system and society. It is using for determine, measures 
and compares the value of pharmaceutical product and services. Pharmacoeconomics 
study also using to evaluate the research method of cost minimization, cost-
effectiveness, cost benefits, cost of illness, cost utility, and quality of life assessment    
(Bootman et al, 1991). 
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1.2. LITERATURE REVIEW 
1.2.1 Fungal infection worldwide  
There are many studies and evaluations of infectious microorganisms during 
the last decade. Based on the studies, fungal diseases appeared to have a higher toll 
as seen with increased morbidity and mortality among patients, thus considering it as 
outstanding. This can be seen particularly in hospitalized patients where the rate of 
Candida species’ bloodstream infection has increased greatly than the previous three 
decades. This increase in fungal infections leads to the increase of mortality and long 
duration of hospitalization.  
Pfaller et al, (1998) reported that the presence of new types of fungal 
microorganism such as Candida krusei, Candida glabrata, Fusarium and 
Trichosporon betgelll lead to an increase in the incidence rate of community 
acquired and nosocomial infections among the patients. The study showed that there 
was significant resistance of antifungal drugs from the nosocomial pathogen of 
fungal.  
  Goldani and Mario, (2003) reported a retrospective review of the clinical 
features, treatment and outcomes of 27 patients with Candida tropicalis fungemia 
which was a common cause of fungemia in Latin America. The study covered a 
period of 4 years at a tertiary Brazilian care hospital. Candida tropicalis cases were 
selected from 101 patients with different Candida species. Among those 101 patients, 
Candida albicans was the most frequently isolated (32.6%), followed by Candida-
tropicalis (26.7%), and Candida parapsilosis (23.7%). The mortality rate among the 
27 patients with Candida tropicalis fungemia, was 48%.   
A USA data from the Surveillance and Control of Pathogens of 
Epidemiological Importance (SCOPE) Program indicated that Candida is the fourth 
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most common cause of nosocomial bloodstream infection, comprising 8% of 
bloodstream infections (Pfaller et al, 1998).  
Another study showed that Candida albicans remained the most commonly 
isolated Candida species. But non-albicans species increase in frequency and often 
have been showing changeable degrees of antifungal susceptibility (Wisplinghoff et 
al., 2004). 
Moreover, (Simpson et al., 2004) of the University of Alberta-Canada 
conducted a morbidity and mortality comparative study among patients with 
asymptomatic funguria. The study was performed among 149 adult patients with 
funguria. During the study period, the incidence of funguria in all hospitalized urine 
specimens was found to be 3%. Laboratory testing was done for 73% of cases out of 
which 70% were identified as Candida albicans. The study revealed that the 
hospitalized adults patients did not benefit from treatment of asymptomatic funguria 
with regards to morbidity or mortality. Nevertheless, the presence of multiple risk 
factors for funguria or invasive fungal infections was associated with a longer 
duration of hospitalization, suggesting that funguria may be a sickness indicator.   
A study about the incidence of Candiduria and fungal urinary tract infection 
(UTI) showed that infections have increased in recent years due to 
immunosuppressive therapy (Guglielmo et al., 1994).  
In addition, the most frequent organism that, causes fungal UTI is still 
Candida albicans followed by Candida (Torulopsis)glabrata, Candida tropicalis,, 
and Candida krusei (Guglielmo et al., 1994). Non-albicans Candida and non-
Candida yeasts are steadily increasing as the etiological cause of fungal UTI. 
Krcmery, et al., (1999) conducted a study on 50 patients hospitalized with 
fungal UTI in Slovak Republic. The numbers of males among the patients were 26, 
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while the total numbers of females were 24 patients.  The patients mean age was 
62.4years. Candida albicans isolated from 36 patients, followed by Candida 
tropicallis (5 patients), Blastoschizomyces capitatus (5 patients), and Candida krusei 
from 4 patients. Two patients had fungaemia, simultaneous significant bacteria were 
present from 20 of 50 patients with fungal UTI (40%). Fluconazole was used in 29 
patients of which 25 of them were cured; ketoconazole was used in 14 patients of 
which 12 of them were cured.  Itraconazole was used in 3 patients and all of them 
were cured.  Systemic amphotericin B was used in the treatment of four patients with 
fungal infections, two of them were cured.  The results also showed that 42 (84%) 
patients from the total number of patients were cured. The analysis result showed the 
significant of systemic antifungal chemotherapy in high-risk patients with fungal 
UTI.   
Beck-Sague et al., (1993) conducted study during 1980-1990.  The result 
showed that there were 30,477 reported cases out of which 26,553 were nosocomial 
fungal infections. The rates of fungal infections were increased during the study 
period from 2.0 to 3.8 infections/1000 patients discharged.  
Also the study showed that the fungal infections rate increased for urinary 
tract infection from (9.0 to 20.5 /1000) patients discharged, for surgical wound 
infection from 1.0 to 3.1, and for pneumonia from 2.3 to 3.6. The nosocomial 
fungemia rate increase from 1.0 to 4.9. The percentage of nosocomial infection by all 
hospitals due to fungal pathogens increased from 6.0% in 1980 to 10.4% in 1990 at 
all major sites of infection. According to the study the surgical wound infections, 
from 1.5% to 5.1%; lung infections, from 5.2% to 5.7%; urinary tract infections from 
6.7% to18.7%, and blood stream infection from, 5.4% to 9.9%. Candida albican was 
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the most frequently isolated fungal pathogen (59.7%), then others Candida species 
(18.6%), Candida albicans infection increase from (52%) in 1980 to (63%) in1990 
Singh et al., (2005) conducted a study in all India Institutes of Medical 
Sciences, in order to do isolation of fungus from the specimen of brain tissue culture 
due to Candida bantianum. The study reported that there was a case of fungal 
granuloma of the brain due to C. bantianum which causes very serious infection to 
the patient’s brain.  
Fungal infections were associated with significantly higher 28-day mortality 
(35) % and in-hospital mortality (57%) than were infections due to another organism, 
the odds ratio for death within 28 days due to fungemia was 2.07 (95%  in 
comparison with that for blood stream infections caused by other organisms (Pittet et 
al.,1997).   
Keady and Thacker, (2005)   confirmed  the increase in the incidence of 
invasive fungal infections, especially those caused by Candida spp. and Aspergillus 
spp. due to the increasing numbers of critically ill and immunocompromised patients.   
According to Tritipwanit, et al., (2005) from Thailand, Candida albicans 
remains the most commonly isolated species of candidemia, accounting for 42.9 
percent of all isolations.  
Lin et al., (2005) from Taiwan documented a case report of 33 years old 
women with invasive fungal infection that has been treated firstly by glucocorticoids 
and prednisolone. Later on after being discharged, patient experienced chest pain and 
fever and returned back to hospital where she was confirmed to be suffering from 
invasive pulmonary aspergillosis and pulmonary cryptococcosis infections. The 
patient was treated by the antifungal agent amphotericin B (IV) for 20 days and 
fluconazole (orally) for 4 months. Latest diagnosis showed normal findings. The 
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authors explained that each possible infectious etiology for pulmonary lesions in 
immunocompromised patients is associated with a significant risk of mortality.  
A study conducted by Nyirjery et al (1995) during the period 1991 to 1993, 
reflected that 74 patients out of 300 had positive fungal culture, among those patients 
68% were Candida albicans, 32% were others' species. Fungal vaginitis remains one 
of the most common infections of the fungal genital tract, it has been estimated that 
approximately 75% of all women will at the same time in their lives, have vaginal 
yeast infections. 
According to the report of the International Conference for the Development 
of a Consensus on the Management and Prevention of Severe Candidal Infections, 
there is an increasing incidence of Candidial infection and Candida represents the 
fourth most common organism isolated from the blood of hospitalized patients 
(Edwards et al., 1997). The report also mentioned that some reasons that lead to the 
increase of candida infections were due to change in the incidence of species to non-
albicans isolate with resistance to antifungal drugs, and the limitation of diagnostics 
for deep fungal infections.  
A prospective surveillance study was conducted by Lopes, (2006) from 
January 1998 until March 2000 in the pediatric hospital in Portugal. The hospital 
contained   units of neonatal intensive care, pediatric intensive care, general surgery, 
haematology, gastroenterology, pneumology/nephrology, infant medicine, general 
medicine and burn units. During the period of the study nosocomial fungal infection 
was identified in 63 children with a total of 67 reported episodes, since one patient 
had four different episodes and another one had two. These incidents are considered 
as new cases because they were spaced more than 1 month. In seven cases death was 
associated with nosocomial fungal infection, accounting for 10.4% of lethality. The 
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accumulated incidence of nosocomial fungal infections was 3.0 per 1000, with a 
mean annual incidence of 1.3 per 1000 populations. In this study, the incident of 
nosocomial fungal infections was occurred more frequently among; males (56.7%), 
among the less age (34.3%) and among the longer hospitalized patients (50.7%).  
fungal organisms which were observed most frequently among the patients were, 
Candida albicans (64.2%), followed by Candida parapsilosis (28.4%), Candida 
tropicalis (6.0%), and Saccharomyces cerevisiae (1.5%). In seven death cases 
associated with nosocomial fungal infection, five were happened due to Candida 
albicans, two (Candida tropicalis) and one (Candida parapsilosis).  
Patel et al (2005) conducted a study that analyzed 119 patients and found that 
50% of them were males, and their mean age was 51.8 year (range 19-85). The study 
observed that the Candida albicans was the species that isolated most frequently 
(41%), followed by Candida parapsilosis (24%), Candida glabrata (20%), Candida 
tropicalis (8%), Candida krusei (4%), Candida lusitamae (2%), and Candida 
gullieeromondi (1%). Fluconazole was the initial choice therapy offered for 75% of 
the patients. 
Stratov et al (1998) conducted study in Australia on 38 patients with 
Candidaemia between 1994 and 1996. The study showed that the incidence of 
Candidaemia was 0.71 per 1000 discharged patients admitted longer than 1 day and 
1.54 per 1000 of discharged who were admitted longer than 5 days. Male percentage 
was 63%, average ages of the patients were 66 years (range 36-80). There were 
underlying illnesses such as gastrointestinal disease present in 66% of the patients, 
solid tumour (eight patients), pancreatic (5 patients), inflammatory colitis (4 
patients), and abdominal surgery (19). The number of patients who were infected 
with genitourinary tract disease was 5 (13%). Some diseases such as hematological 
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malignancies, diabetes mellitus and renal failure had 4 patients for each.  Isolation of 
Candida albicans was positive in 63% of the total infections, 62% of the deaths 
numbers, and 75% of the complications. The study showed that 13 (34%) of the 
patients died, 5 from primary sepsis and 3 from treatment failure. 5 deaths were 
unrelated to Candidaemia. 62% of the deaths occurred among the patients were due 
to candidaemia. Out of 38 patients 8 patients did not receive antifungal therapy. 5 
died septic deaths within 48 hours of blood cultures having been taken, and 3 
survived the episode of Candidaemia with catheter removal. There were 4 
complications, one each of endophthalmitis, septic pulmonary emboli, hepatic 
Candidiasis and splenic Candidiasis. 3 patients survived without sequelae after 
prolonged antifungal therapy (103, 79 and 33 days, respectively), the fourth patients 
died the day after all active treatments were withdrawn.  
Khor and colleagues (2006) reported the epidemiology of fungal keratitis in 
Singapore. They concluded that Fusarium was most prevalent fungal keratitis and 
contributed to significant morbidity.  
In summary, it could be deduced that most of the fungal infections studied 
were from Candida spp. The resultant infections were shown to be from nosocomial 
origins from different continents of the world thereby depicting its worldwide 
coverage. However, other fungal organisms other than Candida spp were also 
studied. 
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1.2.2 Fungal infections in Malaysia 
Up to our knowledge, pharmacoepidemiological evaluation of fungal 
infection in Malaysia has not been conducted extensively. However, few studies 
were performed focusing more on specific types of fungal infections.   
A study was conducted by Ng et al (1999) at the Medical Microbiology 
Department of Malaya University. One thousand one hundred and fourteen fungal 
yeasts were isolated from virus clinical specimens. The study identified a species of 
Candida with the high frequency of Candida albicans (44.2%), Candida parapsilosis 
(26.0%), Candida tropicalis (17.7%), Candida globrata (9.6%), Candida krusis 
(1.2%), Candida rugosa (0.6%), Candida guilliermondii (0.2%), Candida lustaniae 
(0.08%), and Candida keyr (0.8%). The most non-albicans was isolated from the 
blood, respiratory system, urine and skin. The higher number of Candida albicans 
was obtained from the vaginal swabs, then Candida globrata 82.2, and Candida 
kurodei was 64.2%. 
A study was conducted in the National University of Malaysia (UKM) by 
Goh et al. (2005) to determine the incidence of allergic fungal sinusitis. The study 
involved 30 patients of immunocompetent chronic rhinosinusitis who were under 
surgery. Five (16.7%) of the nasal secretions specimens and 11(36.7%) of the 
surgical specimens taken from all patients were found to be fungal-positive. The 
prevalence of allergic fungal sinusitis was found to be 26.7%.  It was also   observed 
that the most common causative agent was Aspergillus.Sp (54.5%). All patients’ 
results were positive in the test done for discovering the skin reactivity to the fungal 
allergen. 
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 As compared to fungal studies reported in other parts of the world, few 
studies were reported from Malaysia. However, the few studies reported were mostly 
from Candida albicans causing vaginal candidiasis. 
 
1.2.3 Risk factors   
A study on fungal urinary tract infections was conducted by Krcmercy et al 
(1999) among 50 hospitalized patients. The study showed that the most frequent risk 
factors for developing of symptomatic fungal urinary tract infections were the use of 
antibiotic drugs with more than one agent in one week   (96%), previous therapy with 
corticosteroids (72%), fungal infection in other parts of the body (48%), urinary 
catheter or nephrostomy (46%), hematological malignancies with neutropenia (30%), 
and diabetes mellitus(12%). The organisms which were isolated from the urinary 
tract were Candida albicans in 36 patients, Candida tropicalis in 5 patients, 
Blastoschizomyces capitatus in 5 patiens, and Candida Krusei in 4 patients.  
In the previous Malaysian study that was conducted by Goh et al. (2005), 
asthma was recognized to be associated with allergic fungal sinusitis in 37.5% (3 out 
of 8 patients) of cases. 25% (2/8 patients) of cases had Aspirin intolerance, and 
62.5% (5/8 patient) had elevated total immunoglobulin E levels. Other risk factors 
have been highlighted in section 1.1.3(f). 
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1.2.4 Antifungal drugs  
1.2.4 (a) Classification of antifungal drugs  
Based on pharmacological action, antifungal drug therapy divided into two 
major types, one is systemic antifungal drugs and the other is topical use of 
antifungal drugs.  
Examples of antifungal drugs such as imidazole, triazole, and polyene can be 
used to treatment either systemic or topical fungal infection. Whereas, there are 
many superficial infections that can be treated either systemically or topically. 
(Bennett, 2001). 
 Zhang et al., (2008) showed that the antifungal drugs are classified according 
to the area of infection in the body into two main types, topical and systemic.  
According to Zhang et al, topical and systemic antifungal drugs are divided into four 
subclasses; polyenes, amidazoles, triazoles and miscellaneous.  
1. Polyenes: includes  amphotericin and nystatin 
2. Amidazoles: such as clotrimazole, ketoconazole, miconazole, econazole, 
fenticonazole, sulconazole, and tioconazole. 
3. Triazoles: fluconazole, itraconazole 
4. Miscellaneous: flucytosine, griseofulvin, terbinafine   
 
i. Topical antifungal drugs  
  The topical antifungal drugs are generally used for the treatment of 
superficial fungal infections, unless the infection is widespread, involve an extensive 
area, or is resistant to initial therapy (Zhang et al., 2008; Bennett, 2001). 
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ii. Systemic antifungal drugs 
These types of antifungal drugs are often used for the treatment of 
Onychomycosis, Tinea capitis, superficial and systemic candidiasis. In addition, the 
systemic antifungal drugs are used for prophylaxis and treatment of invasive fungal 
infections (Zhang et al., 2008).  
Zhang et al (2008) mentioned that the incidents of invasive fungal infections 
have increased in immunocompromised patients due to the development of resistant 
fungi. In addition to that the study mention that several new antifungal drugs have 
confirmed significant therapeutic benefits and have broadened clinicians' choices in 
the treatment of superficial and systemic invasive fungal infections. 
A study done to identify the prophylaxis and treatment of fungal infection in 
patients with haematological malignancies reported that the polyene macrolides, the 
imidazoles and the triazole were the most frequently classes of antifungal drugs that 
are used for prophylaxis and treatment of fungal infections (Ascioglu et al., 2000).   
Usually polyene macrolides contain nystatin and amphotericin B. The 
polyene macrolides causes death of the microorganism’s cell by binding to ergosterol 
in cell membranes, and increased membrane permeability. 
 The imidazole antifungal agents - ketoconazole and miconazole -were used 
less frequently. The imidazole inhibits production of fungal cytochrome P450 (CYP) 
14α-demethylase, thereby disallowing the production of ergosterol. Furthermore, the 
triazole fluconazole and itraconazole have the same mechanism of action as the 
imidazoles. These agents can be found in different formulations for use through 
different routes (Ascioglu et al., 2000). 
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1.2.4 (b) Cost of antifungal drugs 
Study conducted in adults’ patients in USA by Aryun Kim et al, (2010) to 
determine cost of Aspergillosis fungal infection among hospitalization patients in 
United state of America hospital during years from 2000 to 2006. The study was 
looked to the general hospital costs which included length of stay and cost of 
antifungal treatment. The total patients were 1835, from the analysis the total cost for 
1835 patients was $52 803, the researcher mention that the cost of antifungal drugs 
was reduced during years 2005- 2006, more over they mention that the use of 
intravenous voriconazole was associated with reduced  the total hospitalization costs. 
Also they found that the using of amphotericin B or caspofungin independently 
associated with a reduced length of hospital stay. 
Study conducted in Italy by stam WB, et al, (2008) to evaluate and compare 
the cost treatment of caspofungin with liposomal amphotericin B antifungal drugs 
using for treatment patients of neutropenic fever. From the analysis the researcher 
reprted that the using of caspofungin antifungal drug was cost-effective compare to 
liposomal amphotericin B in treatments of patients with neutropenic fever. 
In general there are lack of previous studies regarding the cost of antifungal 
drug, moreover, cannot compare the previous limit study with this study because the 
current study looked only to the cost of antifungal therapy only.  
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1.3 PROBLEM STATEMENT 
Recently, the incidence of fungal infections is raising a great deal of concern 
among researchers, hospital management and even individuals. In view of these 
concerns that have resulted in high morbidity and mortality among patients 
commonly hospitalized, researchers in the western world have dwelt into research to 
find a solution to these problems. On the other hand, Malaysia is not 100 percent free 
of fungal infections in its environment and the hospital in particular. However, little 
studies so far has been carried out and published. In fact, the studies carried out are 
mostly limited to a particular strain of fungus. This study, therefore, aims to 
investigate the epidemiology of fungal infections, types of fungal microbes, to 
determine the prevailing conditions that promoted the spread of fungal 
microorganisms, and to determine the extent of diagnosis and treatment methods 
used in patients in Hospital Universiti Sains Malaysia. 
 
1.4 RATIONALE OF THE STUDY 
Fungal infections are important causes of morbidity and mortality worldwide, 
particularly among immunocompromised patients. As a result of increased cases of 
fungal infection among immunocompromised patients such as cancer and HIV in the 
hospitals, the research aims to investigate the causes of such prevailing condition. 
Moreover, the increased cases of nosocomial fungal infections among patients in the 
hospitals boosted the zeal for such study.   
In addition, patients from different walks of life come down with fungal 
infections and are constantly being treated, but the prevalence of the infection is not 
decreasing rather growing at an alarming rate. Due to this unprecedented scenario, 
the study aims to look into the epidemiology of fungal disease in the area under 
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study. In conclusion, there is limited studies conducted on fungal infections in 
Malaysia in general and HUSM in particular. 
 
1.5 STUDY OBJECTIVES 
1.5.1 General objective 
This study was conducted to study epidemiology of fungal infections and to 
determine the patterns of antifungal drugs use among patients admitted to HUSM 
within 2005 to 2006. 
 
1.5.2 Specific objectives 
This research was conducted specifically to determine; 
1. Prevalence of fungal infection and patterns of antifungal drugs that were used 
in the outpatient’s clinic of University Sains Malaysia during the period from 
January 2005 to June 2005. 
2. The prevalence and types of fungal infections and patterns of antifungal drugs 
that were used among the patients who were admitted to the hospital USM 
during the period from January 2006 to December 2006.   
3. The demographic characteristics of the patients who were admitted to the 
hospital USM during the stated period (i.e. outpatients and inpatients). 
4. The factors and co-morbidities associated with fungal infections.   
5. The outcome statistics of death among hospitalized patients. 
6. The cost of antifungal therapy for the hospitalized patients.  
7. To evaluate the relationships between demography, types of fungal infection, 
types of antifungal drugs, co-morbidities, risk factors and patient’s outcomes 
(i.e survival statistics). 
